Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003694 and Abemaciclib in NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT05372640Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZEN3694 in NUT carcinoma (NC), breast cancer and solid tumor, sponsored by National Cancer Institute. Primary endpoints: Maximum tolerated dose or recommended phase 2 dose at 28 days, Incidence of adverse events up to 5 years and 6 more. Started Aug 2023; status: recruiting.
02
Drugs
ZEN3694
03
Conditions
NUT carcinoma (NC)breast cancersolid tumor
Beyond the preview
Go deeper on NCT05372640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372640.